HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Google Scholar Articles by Axelson, H W Articles by Askmark, H PubMed PubMed Citation Articles by Axelson, H W Articles by Askmark, H

Successful repeated treatment with high dose cyclophosphamide and autologous blood stem cell transplantation in CIDP

¹ Department of Clinical Neurophysiology, University Hospital, Uppsala, Sweden
² Department of Haematology, University Hospital, Uppsala, Sweden
³ Department of Neurology, University Hospital, Uppsala, Sweden

Correspondence to:
Dr H W Axelson, Department of Clinical Neurophysiology, University Hospital, SE-751 85 Uppsala, Sweden; hans.axelson@akademiska.se

The first 150 words of the full text of this article appear below.

Chronic inflammatory demyelinating polyneuropathy (CIDP) is characterised by the occurrence of symmetrical weakness and sensory impairment in arms and legs. The course is relapsing or chronic and progressing. CIDP is considered to be an autoimmune disease, which is supported by the beneficial response to immunomodulating therapies in most patients.¹ Benefit from treatment with corticosteroids, plasmapheresis and intravenous immunoglobulin (IVIG) has been confirmed¹ but not all patients respond. Beneficial effects in previously treatment resistant CIDP have been reported for ciclosporin, etanercept, mycophenolate mofetil, rituximab and pulse cyclophosphamide treatment.¹ In 2002, Brannagan et al² reported long term remission after high dose cyclophosphamide in four patients with CIDP refractory to conventional treatment. The same year Vermeulen and Van Oers³ reported on successful autologous blood stem cell transplantation (ASCT) in one patient with CIDP. To our knowledge, no reports exist on repeated treatment with high dose cyclophosphamide and/or ASCT in CIDP.

We report . . . [Full text of this article]